Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at $7.15, up...

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The increased risk...

After decades of clinical research and false starts, have Brain-Computer Interface (BCI) systems finally arrived? Read BioWorld's special series.

Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai...